Literature DB >> 28571007

Eplerenone Prevents Atrial Fibrosis via the TGF-β Signaling Pathway.

Lili Du1, Mu Qin, Yi Yi, Xiaoqing Chen, Weifeng Jiang, Li Zhou, Daoliang Zhang, Kai Xu, Yiqing Yang, Chao Li, Yan Liu, Xu Liu, Sheng-Zhong Duan.   

Abstract

OBJECTIVES: Eplerenone (EPL), an antagonist of the mineralocorticoid receptor, is beneficial for atrial fibrillation and atrial fibrosis. However, the underlying mechanism remains less well known. We aimed to investigate the effect of EPL on atrial fibrosis using a mouse with selective atrial fibrosis and to explore the underlying mechanisms.
METHODS: EPL-treated MHC-TGFcys33ser transgenic mice that have selective atrial fibrosis (Tx+EPL mice), as well as control mice, were used for in vivo studies including histological analyses, Western blotting, and qRT-PCR studies. TGF-β1-stimulated atrial fibroblasts were treated with EPL or vehicle for the in vitro studies including Western blotting and qRT-PCR studies. In addition, Smad7 siRNA was used to knock down Smad7.
RESULTS: EPL inhibited atrial fibrosis in the Tx mice. In addition, EPL suppressed the expression of fibrosis-related molecules induced by TGF-β1 in vivo and in vitro. This occurred in concert with a downregulation of Smad7 protein expression and an upregulation of p-Smad2/3 protein expression. In addition, knockdown of Smad7 by siRNA abolished the protective roles of EPL.
CONCLUSIONS: EPL inhibited atrial fibrosis in Tx mice. The underlying mechanism may involve increased protein expression of Smad7, which enhances the inhibitory feedback regulation of TGF-β1/Smad signaling.
© 2017 S. Karger AG, Basel.

Entities:  

Keywords:  Atrial fibrosis; Eplerenone; Smad7; TGF-β1

Mesh:

Substances:

Year:  2017        PMID: 28571007     DOI: 10.1159/000471918

Source DB:  PubMed          Journal:  Cardiology        ISSN: 0008-6312            Impact factor:   1.869


  5 in total

Review 1.  Mineralocorticoid receptor activation and antagonism in cardiovascular disease: cellular and molecular mechanisms.

Authors:  Johann Bauersachs; Achim Lother
Journal:  Kidney Int Suppl (2011)       Date:  2022-03-18

2.  Mineralocorticoid Receptor Activation and Atrial Fibrosis.

Authors:  Nancy J Brown
Journal:  Hypertension       Date:  2019-02       Impact factor: 10.190

3.  Mineralocorticoid Receptor Antagonists Eplerenone and Spironolactone Modify Adrenal Cortex Morphology and Physiology.

Authors:  Sofia S Pereira; Liliana Carvalho; Madalena M Costa; Armindo Melo; Isabel M P L V O Ferreira; Celso E Gomez-Sanchez; Mariana P Monteiro; Gavin Vinson; Duarte Pignatelli
Journal:  Biomedicines       Date:  2021-04-20

Review 4.  Immunomodulatory Potential of Diuretics.

Authors:  Paweł Bryniarski; Katarzyna Nazimek; Janusz Marcinkiewicz
Journal:  Biology (Basel)       Date:  2021-12-11

Review 5.  Regional Diversities in Fibrogenesis Weighed as a Key Determinant for Atrial Arrhythmogenesis.

Authors:  Cheng-Chih Chung; Chye-Gen Chin; Yung-Kuo Lin; Yao-Chang Chen; Wan-Li Cheng; Yung-Hsin Yeh; Yu-Hsun Kao; Yi-Jen Chen
Journal:  Biomedicines       Date:  2021-12-14
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.